Estimation of the epidemiological burden of human papillomavirus-related cancers and non-malignant diseases in men in Europe: a review

Table 2 Expected annual number of new human papillomavirus (HPV)-related cancer cases in men in Europe^a

Cancer sites (ICD 10 code)	Expected number of new cancer cases, irrespective of HPV status (bounds)	HPV prevalence by site (%) (95%CI)	Expected number of new cancer cases attributable to HPV (bounds)	Prevalence of HPV 16/18 in HPV-positive cancers (%)	Expected number of new cancer cases attributable to HPV16/18
Head and neck Oral cavity^b Oropharynx^c Larynx (C32)	67,354 (63,443-71,292) 20,133 (18,768-21,514) 20,433 (19,651-21,776) 26,788 (25,210-28,382)	16.0 (13.4-18.8) 28.2^d (24.4-32.2) 21.3 (18.5-24.3) [18]	14,098 (11,455-17,077) 3,221 (2,515-4,045) 5,171 (5030-5311) 5,706 (4,664-6,897)	68.2/34.1 86.7/2.8 69.2/17.0	12,707 3,221 4,567 4,919
Anus (C21)	2,162 (1,722-2,620)	84.2 (81.5-86.9) [19]	1,821 (1,403-2,277)	87.1/6.2	1,699
Penis (C60)	3,178 (2,623-3,751)	46.7 (42.0-51.3) [20]	1,484 (1,102-1925)	60.2/13.4	1,091
Total	72,694 (67,957-77,470)		17,403 (14,049-21,161)		15,497

ICD International Classification of Diseases, CI confidence interval
^a 26 European countries
^b Includes tongue (C01-02), mouth (C03-06), and also includes base of the tongue, which actually belongs to the oropharynx
^c Includes tonsil (C09), other oropharynx (C10), hypopharynx (C12-13) and pharynx unspecified (C14)
^d Except hypopharynx (C12-13), where HPV prevalence is the same as in laryngeal cancer (C32)

ISSN: 1471-2407